SAN JOSE, Calif., Oct. 20 – Starch Medical Inc (SMI), a San Jose, CA-based medical device
manufacturer, announces the first controlled clinical intro/launch of SealFoam(TM) Absorbable
Polysaccharide Hemostat in the European Union and other major international markets.
Introduction of SealFoam(TM) Absorbable Polysaccharide Hemostat will commence this month at
the European Association of Cardio-Thoracic Surgeons congress in Vienna and in November at
the MEDICA congress in Dusseldorf, Germany (booth #16E20).
SealFoam(TM) is the latest addition to the Absorbable Modified Polymer (AMP(TM)) product line
and offers a hemostatic foam (pad) configuration for a wide range of surgical wounds. The ultra
hydrophilic and adhesive properties of SealFoam(TM) are especially formulated to control oozing
or profuse bleeding, and to minimize the possibility of re-bleeding. The pad may also be trimmed
to suit the surgical procedure and is indicated for a diverse range of applications and unique
wound contours.
AMP(TM) technology is a proprietary engineering process that modifies plant starch into
biocompatible, absorbable, hemostatic polysaccharide particles. AMP(TM) particles have a
molecular structure that rapidly absorbs water from blood, causing a high concentration of
platelets, red blood cells and coagulation proteins which accelerate the physiologic clotting
cascade at the bleeding site.
David Lang, President of SMI, states “SealFoam(TM) is currently the only available surgical
hemostatic pad derived from plant starch without animal/human components. The superb efficacy
offers surgeons a safe alternative for achieving hemostasis under various surgical conditions. We
will introduce SealFoam(TM) through our global distribution network and potential partners during
the 4th quarter of this year.”
SMI is a privately-held medical device company engaged in the design, manufacture, marketing
and licensing of breakthrough, hemostatic solutions. Starch Medical’s proprietary, patent-pending
technology platform (AMP(TM)), including powders, foams and films, will focus on the worldwide,
multi-billion dollar biomaterial, hemostasis, and wound care marketplace.
For additional information, distribution inquiries, and licensing options, please visit
www.starchmedical.com.
Contact: Jane Chen of Starch Medical Inc, +1-408-428-9818, jane@starchmedical.com
SOURCE Starch Medical Inc
